- Home
- PLBY vs ACRS Comparison
PLBY vs ACRS Comparison
Compare PLBY & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBY
- ACRS
- Stock Information
- Founded
- PLBY 1953
- ACRS 2012
- Country
- PLBY United States
- ACRS United States
- Employees
- PLBY N/A
- ACRS N/A
- Industry
- PLBY Recreational Games/Products/Toys
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- PLBY Consumer Discretionary
- ACRS Health Care
- Exchange
- PLBY Nasdaq
- ACRS Nasdaq
- Market Cap
- PLBY 147.5M
- ACRS 165.7M
- IPO Year
- PLBY N/A
- ACRS 2015
- Fundamental
- Price
- PLBY $1.47
- ACRS $1.45
- Analyst Decision
- PLBY Hold
- ACRS Strong Buy
- Analyst Count
- PLBY 1
- ACRS 8
- Target Price
- PLBY $0.70
- ACRS $9.71
- AVG Volume (30 Days)
- PLBY 397.1K
- ACRS 755.2K
- Earning Date
- PLBY 08-07-2025
- ACRS 08-06-2025
- Dividend Yield
- PLBY N/A
- ACRS N/A
- EPS Growth
- PLBY N/A
- ACRS N/A
- EPS
- PLBY N/A
- ACRS N/A
- Revenue
- PLBY $116,691,000.00
- ACRS $17,777,000.00
- Revenue This Year
- PLBY $3.96
- ACRS N/A
- Revenue Next Year
- PLBY $1.75
- ACRS $11.77
- P/E Ratio
- PLBY N/A
- ACRS N/A
- Revenue Growth
- PLBY N/A
- ACRS N/A
- 52 Week Low
- PLBY $0.52
- ACRS $1.05
- 52 Week High
- PLBY $2.44
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- PLBY 52.00
- ACRS 51.96
- Support Level
- PLBY $1.40
- ACRS $1.37
- Resistance Level
- PLBY $1.55
- ACRS $1.59
- Average True Range (ATR)
- PLBY 0.07
- ACRS 0.10
- MACD
- PLBY -0.03
- ACRS -0.01
- Stochastic Oscillator
- PLBY 22.88
- ACRS 28.57
About PLBY PLBY Group Inc.
PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.